Hormone therapy and phytoestrogens

被引:18
作者
Lien, LL [1 ]
Lien, EJ [1 ]
机构
[1] UNIV SO CALIF,SCH PHARM,DEPT PHARMACEUT SCI,LOS ANGELES,CA 90033
关键词
D O I
10.1111/j.1365-2710.1996.tb00008.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
As ageing progresses the levels of sex hormones decrease in the human body. In the male population, the decrease or absence of testosterone leads to decreased strength and stamina, thin bones and a low sex drive (1). In the female population, the immediate symptoms of menopause include irregular periods, painful sexual intercourse due to vaginal dryness, hot flushes and night sweats (2). Lack of oestrogen also leads to the risk of developing osteoporosis and cardiovascular diseases. In this report, the authors will mainly discuss the effects of hormone therapy (HT) in menopausal women. Available current clinical data on the effects of calcium supplementation with and without HT, exercise, exercise plus calcium and exercise with HT on bone loss are presented. The effects of transdermal and oral oestrogen therapy (OT) on serum lipids are discussed. Commercially available HT products, their indications, dosages, contra-indications, side-effects and drug interactions are compared. Alternative therapies for menopausal symptoms with Chinese traditional herbs, and a comparison of the molecular structures of phytoestrogens with estradiol and diethylstilbestrol are examined (3, 4). A list of medicinal herbs and foods reported to elicit an oestrogenic response in animals is compiled.
引用
收藏
页码:101 / 111
页数:11
相关论文
共 27 条
[1]  
ALEXANDER W, 1992, AM PHARM, P56
[2]   CALCIUM SUPPLEMENTATION WITH AND WITHOUT HORMONE REPLACEMENT THERAPY TO PREVENT POSTMENOPAUSAL BONE LOSS [J].
ALOIA, JF ;
VASWANI, A ;
YEH, JK ;
ROSS, PL ;
FLASTER, E ;
DILMANIAN, FA .
ANNALS OF INTERNAL MEDICINE, 1994, 120 (02) :97-103
[3]  
BAYS HE, 1994, PROGR DRUG RES, V43, P19
[4]  
BIRO S, 1995, PHARM TODAY, V1, P7
[5]   ESTROGEN REPLACEMENT THERAPY AND RISK OF FATAL COLON-CANCER IN A PROSPECTIVE COHORT OF POSTMENOPAUSAL WOMEN [J].
CALLE, EE ;
MIRACLEMCMAHILL, HL ;
THUN, MJ ;
HEATH, CW .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (07) :517-523
[6]  
*CHIANG SU NEW MED, 1979, CHON YAO DA TZE DIAN, P181
[7]   COMPARISON OF TRANSDERMAL AND ORAL ESTROGEN-PROGESTIN REPLACEMENT THERAPY - EFFECTS ON SERUM-LIPIDS AND LIPOPROTEINS [J].
CROOK, D ;
CUST, MP ;
GANGAR, KF ;
WORTHINGTON, M ;
HILLARD, TC ;
STEVENSON, JC ;
WHITEHEAD, MI ;
WYNN, V .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (03) :950-955
[8]  
Das A, 1994, Prog Drug Res, V42, P133
[9]  
Das Arima, 1994, Pharmaceutical Research (New York), V11, pS118
[10]   ASSOCIATION BETWEEN INCREASED ESTROGEN STATUS AND INCREASED FIBRINOLYTIC POTENTIAL IN THE FRAMINGHAM OFFSPRING STUDY [J].
GEBARA, OCE ;
MITTLEMAN, MA ;
SUTHERLAND, P ;
LIPINSKA, I ;
MATHENEY, T ;
XU, P ;
WELTY, FK ;
WILSON, PWF ;
LEVY, D ;
MULLER, JE ;
TOFLER, GH .
CIRCULATION, 1995, 91 (07) :1952-1958